Aeterna Zentaris Inc (NASDAQ:AEZS)

CAPS Rating: 3 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.


Player Avatar zzlangerhans (99.85) Submitted: 3/7/2012 10:32:45 PM : Underperform Start Price: $11.40 AEZS Score: +13.03

I've covered the Jeremy Richards issue in my pitch on Keryx here:

Both Aeterna Zentaris and Keryx have had high-profile failures in the last few years prior to the emergence of perifosine. For Aeterna is was cetrorelix and for Keryx it was Sulonex. Both companies were essentially declared non-viable by the market in early 2009 yet roared back to life. Three years later, their share prices would be decimated by the failure of perifosine but it is worthwhile to remember that each company has another pipeline candidate in the shadows waiting to assume primacy. I won't be betting on the outcome of the perifosine phase III trial, but I will look closely for an overreaction to negative perifosine news. These companies have shown an amazing ability to return from the brink of disaster.

Featured Broker Partners